



Students for Patient Advocacy Nationwide

1702 Clifton Road Suite 1650
Atlanta, GA 30322
www.spanationwide.org

The Honorable Clint P. Moses, Chair
Wisconsin State Assembly Committee on Health, Aging and Long-Term Care
100 N Hamilton St, Madison, WI 53703
October 19, 2025

Re: Assembly Bill 62 (Subeck) – Support if Amended

Dear Chairman Moses and members of the Committee on Health, Aging, and Long Term Care,

Students for Patient Advocacy Nationwide (SPAN) appreciates the intent of Assembly Bill 62, which aims to make healthcare more affordable and transparent, while improving patient access for Wisconsin patients. We recognize the importance of legislation that addresses high drug prices and unregulated markets.

Yet, as written, we find that this would not effectively combat the intentions of this bill, for various reasons underlined in this letter. This is why we are **requesting specific amendments** that would strengthen the bill's impact and success, ensuring it fully serves the communities it intends to support.

We are particularly concerned about the following aspects of the bill in its current form:

- **Lack of Oversight for PSAOs: Section 601.56** introduces oversight for PSAOs (Pharmacy Services Administrative Organizations) in the form of licensure, but omits ethical monitoring and/or auditing. What this does is create a regulatory gap where entities that influence how drugs are distributed and marketed operate without auditing, creating conflicts of interest.
- **Drug Importation: Section 601.575** limits the importation of drugs to just from Canada, while not defining a clear system for verifying drug quality and improving safety. This is important for 2 reasons: one is that the flow of cheaper drugs are limited, and we don't have safety regulations in check.

To address these concerns, we propose the following amendments:

- **Revise Ethical Monitoring:** Add a provision requiring biannual audits for PSAOs, submitting it and making it publicly accessible. This way, the bill would ensure ethical standards are met and entities which manage billions in the distribution and marketing of drugs are free from conflicts of interest and are transparent.
- **Import Drugs from More Countries:** Amend **Section 601.575** to allow the importation of drugs from the EU and Mexico, while ensuring quality control. Studies show that



drugs from Mexico and the European Union are generally 25-30% cheaper than drugs from Canada. To mitigate quality concerns, add a provision to ensure that lot-testing must be mandated to ensure authenticity. This will allow cheaper drugs than already outlined, making it a win-win for consumers.

We believe these changes will help ensure the bill will make drugs cheaper, while ensuring transparency in both the pharmaceutical industry and quality control, making it a win-win for people. We are eager to see AB 62 succeed in a way that aligns with both expert consensus and community needs.

Sincerely,

Arnav Goyal

arnav.goyal@spanationwide.org | (614)-301-2260

Students for Patient Advocacy Nationwide (SPAN)